Ticker Details
Protalix BioTherapeutics, Inc. Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.
IPO Date:	June 1, 1998
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$191.76M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.15 | 3.27%
Avg Daily Range (30 D):	$0.08 | 3.37%
Avg Daily Range (90 D):	$0.07 | 3.04%

Institutional Daily Volume
Avg Daily Volume:	.5M
Avg Daily Volume (30 D):	.63M
Avg Daily Volume (90 D):	.65M

Trade Size
Avg Trade Size (Sh.):	340
Avg Trade Size (Sh.) (30 D):	144
Avg Trade Size (Sh.) (90 D):	136

Institutional Trades
Total Institutional Trades:	286
Avg Institutional Trade:	$1.6M
Avg Institutional Trade (30 D):	$2.54M
Avg Institutional Trade (90 D):	$1.59M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$4.65M
Avg Closing Trade (30 D):	$2.54M
Avg Closing Trade (90 D):	$1.59M
Avg Closing Volume:	622.3K

News

Aug 19, 2026 @ 2:08 PM Protalix (PLX) Q2 2026 Earnings Call Transcript Source: Motley Fool Transcribing

Mar 9, 2026 @ 10:00 AM Chiesi Global Rare Diseases and Protalix BioTherap... Source: Chiesi Global Rare Diseases / Protalix Biotherapeutics

Mar 26, 2025 @ 7:00 PM [Latest] Global Fabry Disease Treatment Market Siz... Source: Custom Market Insights

Jun 12, 2024 @ 3:45 PM Pluxee to acquire Cobee, an innovative Spanish dig... Source: Pluxee N.V

Jun 12, 2024 @ 3:45 PM Pluxee signe un accord pour l’acquisition d... Source: Pluxee N.V

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$.24	$.05	$.23
Diluted EPS	$.23	$.05	$.22
Revenue	$80.62M	$19.9M	$33.75M
Gross Profit	$55.79M	$12.13M	$29.62M
Net Income / Loss	$18.95M	$3.78M	$18.32M
Operating Income / Loss	$23.29M	$4.67M	$21.15M
Cost of Revenue	$24.83M	$7.76M	$4.13M
Net Cash Flow	$9.19M	$-14.04M	$26.4M
PE Ratio

Splits
Dec 20, 2019	1:10
Jan 03, 2007	1:10